drugset

drugset / Trial / NCT04098432

STR + Anti PD-1 Therapy in Patients with Locally Advanced Unresectable Pancreatic Adenocarcinoma

NCT04098432 ↗

Phase 1/2 Completed 15 enrolled University Hospital Hradec Kralove Bristol-Myers Squibb · collab GCP-Service International s.r.o. · collab

NaSingle-groupOpen-labelTreatment

Summary

Stereotactic Radiotherapy + Anti PD-1 Therapy in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma

Timeline

Start: 2018-12-03
Primary completion: 2022-09-30
Completion: 2022-09-30

Publications

Vosmik M, John S, Dvorak J, Mohelnikova-Duchonova B, Melichar B, Lohynska R, Ryska A, Banni AM, Krempova J, Sirak I. Stereotactic Radiotherapy Plus Nivolumab in Patients with Locally Advanced Pancreatic Cancer: Results from Phase 1/2 Clinical CA209-9KH Trial. Oncol Ther. 2024 Dec;12(4):817-831. doi: 10.1007/s40487-024-00309-z. Epub 2024 Oct 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Nivolumab	Monoclonal antibody	3 mg/kg	Intravenous

Indications